The stock market may be facing more than just a ‘lost decade’
The stock market’s prospects over the next decade are mediocre at best.
Amgen’s stock may see worst day in 24 years as weight-loss-drug data underwhelms
Amgen’s MariTide achieved up to 20% weight loss in a mid-stage trial, but analysts were expecting up to 25%.
Dick’s Sporting Goods sees earnings boosted by strong back-to-school season
The retailer beat estimates for the third quarter and raised its guidance.
There’s more room for risk assets to rally — focus on policy, not politics, HSBC says
The backdrop for stocks is supportive despite the day-to-day Washington machinations
Home-price growth has ‘stalled,’ Case-Shiller says
The Case-Shiller 20-city home-price index rose 4.6% year over year in September.
Why the ‘debasement trade’ lifting bitcoin and gold may continue, says JPMorgan
The financial alternatives to the dollar may have further room to run, says a JPMorgan team.
Eli Lilly’s weight-loss and diabetes drugs are no longer in shortage, says FDA
The U.S. Food and Drug Administration said Eli Lilly’s diabetes and weight-loss drugs marketed as Zepbound and Mounjaro are no longer in shortage signaling that the company has succeeded in expanding manufacturing.
Why Salesforce’s stock is getting more love from Wall Street analysts lately
Salesforce shares have lagged the S&P 500 this year but could be primed for bigger gains thanks to improved product positioning.
Jobless claims inch higher, but still no sign of major U.S. layoffs
The number of Americans who applied for unemployment benefits last week rose slightly to a minuscule 225,000, affirming that layoffs remain surprisingly low even though many companies have pulled the plug on hiring.